Glutathione S-transferase polymorphisms in osteosarcoma patients

Pharmacogenetics and Genomics

Volumn 20, Issue 8, 2010, Pages 507-515

  Salinas Souza, Carolina ^a   Petrilli, Antonio S ^a   De Toledo, Silvia R C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

genetic polymorphism; glutathione S transferase; GSTM1; GSTM3; GSTT1; osteosarcoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE T1; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLEX POLYMERASE CHAIN REACTION; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 77954959941     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833caa45     Document Type: Article

References (32)

1. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997; 44:973-989.
2. Fuchs B, Zhang K, Schabel A, Bolander ME, Sarkar G. Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene 2001; 278:245-252.
3. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976; 37:1-11.
4. Scotlandi K, Serra M. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996; 56:2434-2439.
5. Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact 2002; 2:549-551.
6. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445-600.
7. Wang X, Zuckerman B, Pearson C, Kaufman G, Chen C, Wang G, et al. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA 2002; 287:195-202.
8. Abdel-Rahman SZ, el-Zein RA, Anwar WA, Au WW. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996; 107:229-233.
9. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993; 14:1479-1481.
10. Chenevix-Trench G, Young J, Coggan M, Board P. Glutathione S-tranferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis 1995; 16:1655-1657.
11. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 1995; 4:253-259.
12. Inskip A, Elexperu-Camiruaga J, Buxton N, Dias PS, MacIntosh J, Campbell D, et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J 1995; 312:713-716.
13. Peters U, Preisler Adamz S, Hebeisen A, Hahn M, Seifert E, Lanvers C, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11:639-643.
14. Huvos AG. Bone Tumors: diagnosis, treatment, and prognosis. Saunders: Philadelphia; 1991.
15. Meyer UA. Introduction to pharmacogenomics: promises, opportunities, and limitations. In: Licinio J, Wong M-L, editors. Pharmacogenomics: the search for individualized therapies. Germany: Wiley-VCH; 2002. pp. 1-8.
16. Barnette P, Scholl R, Blandford M, Ballard L, Tsodikov A, Magee J, et al. High-throughput detection of glutathione S-transferase polymorphic alleles in a pediatric cancer population. Cancer Epidemiol Biomarkers Prev 2004; 13:304-313.
17. Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003; 12:527-533.
18. Anttila S, Hirvonen A, Vainio H, Husgafvel-Pursiainen K, Hayes JD, Ketterer B. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 1993; 53:5643-5648.
19. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61:154-166.
20. Romieu I, Sienra-Monge JJ, Raḿ?rez-Aguilar M, Moreno-Mac?́as H, Reyes-Ruiz NI, Estela del Ŕ?o-Navarro B, et al. Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. Thorax 2004; 59:8-10.
21. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett 2008; 266:53-59.
22. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009; 35:18-31.
23. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA, et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19:1279-1287.
24. Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 2002; 16:203-208.
25. Park BK, Kitteringham NR, Powell H, Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153:39-60.
26. Kitteringham NR, Powell H, Henderson CJ, Wolf CR, Park BK. Protection against paracetamol hepatotoxicity in glutathione S-transferase pi knockout mice does not involve altered covalent binding. Br J Clin Pharmacol 1999; 48:887-888.
27. Chacko P, Joseph T, Mathew BS, Rajan B, Pillai MR. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res 2005; 581:153-163.
28. Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I, Vannais D, et al. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet 1993; 53:220-233.
29. Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus AM, Hayes JD, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 1995; 16:707-711.
30. Anttila S, Luostarinen L, Hirvonen A, Elovaara E, Karjalainen A, Nurminen T, et al. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res 1995; 55:3305-3309.
31. Yengi L, Inskip A, Gilford J, Alldersea J, Bailey L, Smith A, et al. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res 1996; 56:1974-1977.
32. Hand PA, Inskip A, Gilford J, Alldersea J, Elexpuru-Camiruaga J, Hayes JD, et al. Allelism at the glutathione S-transferase GSTM3 locus: interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. Carcinogenesis 1996; 17:1919-1922.